Show/hide main menu


Lymphoma Immunology

Team Leader

Dr Alan G. Ramsay
Senior Lecturer in Lymphoma Biology

Tel: +44 (0)20 7848 5816


Dr Ramsay's Profile

Dr. Ramsay leads a research group focussing on translational research in cancer immunology. His research in the chronic lymphocytic leukaemia (CLL) and lymphoma field has characterised novel tumour cell-induced T-cell immune evasion mechanisms and translated bench science to clinical trials with immunotherapy (Ramsay et al JCI 2008) (Shanafelt and Ramsay et al Blood 2013) (Ramsay Br. J Haematol. 2013).

This work includes pre-clinical defintion of CLL (Ramsay et al Blood 2012) and lymphoma (Ramsay et al Blood 2009) tumour cells co-opting multiple immune checkpoint (IC) molecules to suppress T-cell lytic immune synapse function ('adaptive immune resistance').



Current research focus

Understanding and overcoming ‘microenvionmental immunosuppression’ in order to identify new targets for repairing anti-tumour immunity.

Personal awards

2014  – 2016               British Society for Haematology (BSH) Investigator Start-up Fellowship.

2010 – 2012                European Hematology Association (EHA) Research Fellowship.

Academic activities

  • PhD PostGraduate Coordinator (PGC) for Haemato-Oncology, Division of Cancer.
  • Undergraduate and MSc/Res teaching and project supervision.

Selected Publications

  1. Kater AP, Tonino SH, Egle A, Ramsay AG. How does lenalidomide target the chronic lymphocytic leukemia microenvionment? Blood. 2014
  2. Kiaii S, Clear AJ, Ramsay AG, Davis D, Sangaralingam A, Lee A, Calminici M, Neuberg D, Gribben JG. Follicular lymphoma cells induce changes on T-cell gene expression and function – potential impact on survival and risk of transformation. J Clin Oncol. 2013; 31(21):2254-61.
  3. Shanafelt TD, Ramsay AG (co-first author), Zent CS, Leis J, Tun HW, Call TG, LaPlant B, Bowen D, Pettinger A, Jelinek DF, Hanson CA, Kay NE. Long-term repair of T-cell synapse activity in a phase 2 trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia. Blood. 2013;121(20):4137-4141.
  4. Ramsay AG, Evans R, Kiaii S, Svensson L, Hogg N, Gribben JG. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood. 2013; 121(14):2704-2714.
    (InsideBlood research highlight)
  5. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T cell immunological synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.
    Blood. 2012;120(7):1414-1421.
  6. Ramsay AG. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. Br J Haematol. 2013;162(3):313-325.
  7. Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009;114(21):4713-4720.
  8. Gorgun G, Ramsay AG (co-first author), Holderried TA, et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA. 2009;106(15):6250-6255.
  9. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;Jul;118(7):2427-2437.
  10. Ramsay AG, Keppler MD, Jazayeri M, et al. HS1-associated protein X-1 regulates carcinoma cell migration and invasion via clathrin-mediated endocytosis of integrin alphavbeta6. Cancer Res. 2007;67(11):5275-5284.
Sitemap Site help Terms and conditions  Privacy policy  Accessibility  Modern slavery statement  Contact us

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454